TITLE

The Angiogenic Activity of Ascites in the Course of Ovarian Cancer as a Marker of Disease Progression

AUTHOR(S)
Gawrychowski, Krzysztof; Szewczyk, Grzegorz; Różewska, Ewa Skopińska; Malecki, Maciej; Barcz, Ewa; Kamiński, Paweł; Miedzińska-Maciejewska, Magdalena; Śmiertka, Wacław; Szukiewicz, Dariusz; Skopiński, Piotr
PUB. DATE
January 2014
SOURCE
Disease Markers;2014, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Ovarian cancer cells are able to create invasive implants in the peritoneum and their growth is directly associated with the angiogenetic potential. This effect is probably stimulated by vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8), which are both found in ascites. The aim of this study was to assess the influence of ascites produced by ovarian cancer on the angiogenesis. Peritoneal fluid was collected from patients with advanced ovarian cancer; cancer cells were separated from CD45+ leukocytes. Angiogenesis was assessed in mice, after intradermal injection of full cellular suspension together with supernatant or phosphate buffered saline, purified cancer cells suspension, or CD45+ leukocytes suspension. The angiogenesis index (AI) was assessed after 72 hours. VEGF and Il-8 were measured in the supernatant and cellular suspension. AI was the highest in the isolated cancer cells suspensions as well in the group stimulated with supernatant. Both VEGF and IL-8 were high in supernatants from ascites rich in cancer cells (>45%). A significant correlation was revealed between IL-8 concentration and AI. We conclude that ascites in patients with advanced ovarian cancer stimulates angiogenesis and this mechanism is dependent mostly on cancer cells activity and enhanced by cooperation with infiltrating leukocytes.
ACCESSION #
100436733

 

Related Articles

  • Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. McEvoy, Lynda M.; O'Toole, Sharon A.; Spillane, Cathy D.; Martin, Cara M.; Gallagher, Michael F.; Stordal, Britta; Blackshields, Gordon; Sheils, Orla; O'Leary, John J. // BMC Cancer;Jul2015, Vol. 15 Issue 1, p1 

    Background: Ovarian cancer is associated with poor long-term survival due to late diagnosis and development of chemoresistance. Tumour hypoxia is associated with many features of tumour aggressiveness including increased cellular proliferation, inhibition of apoptosis, increased invasion and...

  • CA125—A Test with a Change of Heart Sikaris, Kenneth A. // Heart, Lung & Circulation;Oct2011, Vol. 20 Issue 10, p634 

    CA125 is well known as a tumour marker for ovarian cancer. Like all tumour markers it is not specific for a specific tumour and may be elevated in benign disease. Even in ovarian cancer it seems that CA125 is derived from mesothelial production rather than from the cancer cells. CA125 is a...

  • Bioinformatics.  // Patient Care for the Nurse Practitioner;Aug2002, Vol. 5 Issue 8, p13 

    The article focuses on the potential of microarray technology, that allows processing of vast arrays of blood constituents, to develop new biomarkers. Proteomics is a global discovery approach that makes use of serum, plasma, urine or other secretions to identify the role of proteins in disease....

  • p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Flak, Magdalena B.; Connell, Claire M.; Chelala, Claude; Archibald, Kyra; Salako, Michael A.; Pirlo, Katrina J.; Lockley, Michelle; Wheatley, Sally P.; Balkwill, Frances R.; McNeish, Iain A. // Molecular Cancer;2010, Vol. 9, p175 

    The oncolytic adenovirus dl922-947 replicates selectively within and lyses cells with a dysregulated Rb pathway, a finding seen in > 90% human cancers. dl922-947 is more potent than wild type adenovirus and the E1B-deletion mutant dl1520 (Onyx-015). We wished to determine which host cell factors...

  • New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. Leo, A. Di; Claudino, W.; Colangiuli, D.; Bessi, S.; Pestrin, M.; Biganzoli, L. // Annals of Oncology;Dec2007 Supplement 12, Vol. 18, p8 

    Despite significant improvements in the treatment and outcomes of early-stage breast cancer, the quest continues to find biological and molecular markers that would enable earlier diagnosis or better prediction of treatment efficacy and toxicity. Metabolomics—the latest and one of the...

  • HCSD: the human cancer secretome database. Feizi, Amir; Banaei-Esfahani, Amir; Nielsen, Jens // Database: The Journal of Biological Databases & Curation;2015, Vol. 2015, p1 

    The human cancer secretome database (HCSD) is a comprehensive database for human cancer secretome data. The cancer secretome describes proteins secreted by cancer cells and structuring information about the cancer secretome will enable further analysis of how this is related with tumor biology....

  • MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells. Jian Wu; Alin Ji; Xiao Wang; Yi Zhu; Yasai Yu; Yiwei Lin; Yunfu Liu; Shiqi Li; Zhen Liang; Xin Xu; Xiangyi Zheng; Liping Xie // Journal of Translational Medicine;9/6/2015, Vol. 13 Issue 1, p1 

    Background: An increasing number of studies have demonstrated that deregulation of microRNAs (miRNAs) was a common event in tumor tissues and miRNAs would be treated as ideal tumor biomarkers or therapeutic targets. miR-195-5p (termed as miR-195 for briefly in the following part) was suggested...

  • Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Crea, Francesco; Hurt, Elaine M.; Mathews, Lesley A.; Cabarcas, Stephanie M.; Lei Sun; Marquez, Victor E.; Danesi, Romano; Farrar, William L. // Molecular Cancer;2011, Vol. 10 Issue 1, p40 

    Background: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with...

  • Exosome-derived miRNAs and ovarian carcinoma progression. Vaksman, Olga; Tropé, Claes; Davidson, Ben; Reich, Reuven // Carcinogenesis;Sep2014, Vol. 35 Issue 9, p2113 

    Ovarian carcinoma supernatants have unique exosomal miRNA signature. High levels of exosomal miRNA 21, 23b and 29a are associated with poor survival. Malignant effusion-derived exosomes affect spheroid expansion and mesothelial clearance in vitro and tumor growth in vivo.The objective of this...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics